Intellia Therapeutics Inc (LTS:0JBU)
$ 11.86 0 (0%) Market Cap: 1.22 Bil Enterprise Value: 662.64 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 51/100

Intellia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 07:15PM GMT
Release Date Price: $102.55 (+2.06%)
Michael Peters

Good afternoon, everyone, and thank you for joining us today. My name is Michael Peters, and I'm an analyst in JPMorgan's Healthcare Investment Banking Group.

In this session, we're delighted to introduce Intellia Therapeutics, a leading stage genome editing company, leveraging CRISPR-based technologies. If you have any questions throughout the presentation, please submit them by clicking the blue button at the bottom of your screen, and we'll address them at the end of the prepared remarks.

With that, I'm pleased to introduce you to John Leonard, CEO of Intellia.

John M. Leonard
Intellia Therapeutics, Inc. - President, CEO & Director

Thank you. Good afternoon. I'm John Leonard, President and CEO of Intellia Therapeutics, and I'm pleased to be starting off the year presenting at the JPMorgan 40th Annual Healthcare Conference.

As we enter 2022, it's apparent that genome editing holds the power to revolutionize medicine by treating disease in ways that were inconceivable prior to the Nobel Prize-winning discovery of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot